This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Progenics Pharmaceuticals Presents PSMA-Related Data At SNMMI 2013

TARRYTOWN, N.Y., June 10, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced that it has reported findings from studies of two of its oncology product candidates at the 2013 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in Vancouver, Canada.

Data from studies of MIP-1095, a PSMA targeting small molecule radiotherapeutic, and 99mTc-MIP-1404, a PSMA targeted imaging agent, are featured in oral presentations. Both product candidates are recent additions to Progenics' expanded oncology pipeline following the company's acquisition of Molecular Insight Pharmaceuticals, Inc. Abstracts for these presentations are available on the Events section of Progenics' website:

Oral Presentation #119: Enhancement of prostate-targeted radiotherapy using [131I] MIP-1095 in combination with radiosensitizing chemotherapeutic drugs

Oral Presentation #281: PSMA targeted SPECT imaging biomarker to detect local and metastatic prostate cancer (PCa): Phase I studies with 99mTc-MIP-1404

Robert J. Israel, M.D., senior vice president of medical affairs and clinical research for Progenics, commented, "Ongoing studies of product candidates targeted to PSMA, an enzyme expressed on the neovasculature of almost all prostate cancer cells, potentially could lead to the development of highly specific prostate cancer imaging and treatment options. We are developing candidates that could improve outcomes for cancer patients, including the two candidates featured here at SNMMI in oral presentations as well as our phase 2-stage PSMA antibody-drug conjugate."

Additionally, Progenics is presenting details of its oncology pipeline at exhibit booth #142 at the Meeting.

About MIP-1095, a PSMA targeting small molecule radiotherapeutic

MIP-1095 is in preclinical development for the treatment of metastatic prostate cancer. The compound is radiolabeled with the therapeutic radionuclide, iodine-131, a beta-particle-emitting radionuclide capable of destroying tumor cells. The anticancer effect of 1095 relies on its ability to deliver lethal doses of radiation to prostate cancer cells while causing minimal damage to healthy surrounding tissue.

Stock quotes in this article: PGNX 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs